Set sail for the future - Cell Therapy International Summit Forum was successfully held, and Shenzhen Cell Valley · South China Cell Factory was officially put into operation
Mr. Wang Zhizhen, Academician of Chinese Academy of Sciences, Mr. Liao Shuhua, Director of the Standing Committee of the People's Congress of Pingshan District, Mr. Deng Yandong, Member of the Standing Committee of the Party Committee of Pingshan District and Vice Director of the People's Government of Pingshan District, Mr. Lu Hongzhou, President of the Third People's Hospital of Shenzhen and Academician of the American Academy of Microbiology, Mr. Wang Deping, Academician of the Ukrainian Foreign Academy of Engineering and President of Shenzhen Xinjingshen Center for the Promotion of Biotechnology Achievements, Dr. Shen Hao, tenured professor at the University of Pennsylvania, Chief scientific Officer of Fosun Kite Biotechnology Co., LTD., former FDA drug reviewer, Avalon globocare Co., a NasdaQlisted company in the United States. Dr.David Jin, CEO; Dr.Zhen Zhao, Professor of Cornell University Medical College and Director of the Laboratory of New York Presbyterian Hospital; Wang Ping, Vice President of Shenzhen Institute of Drug Testing; Duan Jiexin, Deputy Secretary of Food and Drug College, Shenzhen Polytechnic University; Chen Junhui, director of Interventional and Cell Therapy Center of Peking University Shenzhen Hospital and President of Cell Medicine Branch of China Food and Drug Promotion Association, and other leaders and top experts from home and abroad attended the event!
At the launch ceremony, Shi Yuanyuan, chairman of Shenzhen Cell Valley, first expressed warm welcome and heartfelt thanks to the leaders and guests. He said that in recent years, the global cell medicine industry has made many achievements in the precision treatment of cancer and other diseases, and the cell medicine industry is gradually considered to be an important emerging technology support industry in the future. The official landing of Shenzhen Cell Valley · South China Cell Factory project into operation and production has condensed the efforts of all those who pay close attention to the industry and the development of Shenzhen Cell Valley, and Shenzhen Cell Valley has made steady progress step by step, and has obtained the performance with industry influence.
Shi Yuan said that Shenzhen Cell Valley will continue to improve technology and production processes to meet market demand and clinical application requirements, through continuous innovation and cooperation, to provide better treatment options for cancer patients, for the domestic cell therapy industry to solve the core raw material retroviral vector of domestic alternative card points, for human health escort.
Liao Shuhua, director of the Standing Committee of Pingshan District People's Congress, said in his speech that in recent years, Pingshan has made continuous efforts in industrial planning, policy support and platform construction to actively promote the development of the biomedical industry, and has achieved remarkable results. Today, Pingshan has become a popular destination for many international biomedical companies and innovative drug research centers, attracting many well-known companies and talents. As a key project of cell and gene therapy industry in Pingshan District, Shenzhen Cell Valley · South China Cell Factory will provide services and technical support for more enterprises, promote cell and gene therapy technology from laboratory to clinical, and promote the development of people's health. I wish Shenzhen Cell Valley more outstanding achievements in the future development road.
Wang Zhizhen, academician of the Chinese Academy of Sciences, said Shenzhen is a leader in the country's reform and opening up, and has maintained its development advantages in recent years, especially in the field of life medicine. Shenzhen Cell Valley Biomedicine Co., Ltd. has always practiced the concept of "cells benefit all beings, genes create the future", focused on key difficulties, breakthrough technology industrialization problems, become the only domestic master industrial retrovirus carrier technology (PackRV-SS system) CRO/CDMO one-stop outsourcing service provider, The cell therapy research system and four service platforms have been successfully established to promote scientific research to clinical practice. Now, Shenzhen Cell Valley has officially put into full production and operation in Pingshan District, Shenzhen, marking the maturity and growth of Shenzhen Cell Valley. In the future, Shenzhen Cell Valley will seek common plans for biomedical development with more than 100 experts and elites from home and abroad. Academician Wang Zhizhen mentioned that science and technology enterprises should support young science and technology talents to "take the lead" and "be the protagonist"; Actively promote the youth of scientific research project leaders and research backbone team, and extend warm congratulations to Shenzhen Cell Valley and wish the conference a complete success.
At the conference site, Shenzhen Cell Valley held a strategic cooperation signing ceremony with Shenzhen Institute of Drug Testing and Food and Drug College of Shenzhen Vocational and Technical University, and will carry out comprehensive cooperation on the establishment of testing standards in the field of cell therapy and the construction of vocational education and cultivation platform for technical talents. Jointly contribute to the domestic production of cell therapy products and the high-quality and rapid development of the whole industry chain in the field of cell therapy, and build the ecology of the cell therapy industry.
On the afternoon of December 16, experts and scholars at home and abroad gathered in Shenzhen Cell Valley Conference Center to hold an academic forum to share the industry trends and breakthroughs in cell therapy in recent years.
The forum began with a speech by Chen Junhui, president of the Cell Medicine Branch of China Food and Drug Promotion Association. Chen Junhui said that the continuous emergence of technological innovation and policy support have significantly accelerated the progress of cell therapy in clinical research and transformation applications, greatly increased the scale of the industry, and China's original research force has gradually moved to the forefront of the world. Top scholars and clinical experts in the industry share cutting-edge information and technology, and will truly make positive contributions to the protection of patients and people's life and health.
Next, top experts and scholars at home and abroad will give keynote lectures.
Professor Li Ling, National Center for Molecular Medicine Transformation, Air Force Military Medical University, gave a keynote lecture entitled "Metabolic Characteristics and Fate Regulation of tumor stem cells".
Dr. Shen Hao, Chief Scientific Officer of Fosun Kat Biotechnology Co., LTD., delivered A keynote lecture entitled "Immunotherapy for Cancer Cure and Beyond-A Historical Mission".
Dr. Zhen Zhao, professor of Medicine at Cornell University, presented the book Companion diagnostics of Adeno-Associated Virus (AAV) antibody screening for gene therapy "keynote lecture.
Wan Xiaochun, Deputy Director of the Institute of Biomedicine and Technology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, gave a keynote lecture entitled "Exploration of immune cell therapy in the treatment of solid tumors".
Guo Zhi, director of the Department of Hematology, Union Shenzhen Hospital, Huazhong University of Science and Technology, gave a lecture entitled "Immunotherapy of blood tumors".
Professor Xia Jianchuan, Center of Biotherapy, Affiliated Cancer Hospital of Sun Yat-sen University, gave a keynote lecture entitled "Research and Development and Clinical Application of New immune cell therapy technology Targeting Malignant solid Tumors".
Yan Xiyun Research group of the Institute of Biophysics, Chinese Academy of Sciences researcher Duan Hongxia gave a keynote lecture entitled "Novel CAR-T Design to Help solid tumor Treatment".
Zhao Lijun, head of R&D department of Shenzhen Cell Valley Biomedicine Co., Ltd. gave a keynote lecture entitled "Selection of viral vectors for Cell therapy".
Then chaired by President Chen Junhui, Wang Deping, Chairman of Shenzhen Xinjingshen Biotechnology Achievement Transformation Promotion Center, Dr. David Jin, former drug reviewer of US FDA, Lu Hongzhou, President of Shenzhen Third People's Hospital (video link), Jiang Hua, Director of Hematology and Oncology Department of Guangzhou Women's and Children's Hospital, and Zhang Caiwan, Secretary General of Shenzhen Biomedicine Promotion Association, held an expert dialogue. Share the cutting-edge progress of the cell industry at home and abroad, discuss the new trend of the international and Chinese cell therapy industry, focus on the cutting-edge technology and clinical practice of cell therapy for in-depth analysis, to achieve the needs of patients, continue to optimize the whole process of cell therapy management, and jointly seek a consistent view of the path of development.
Academician Wang Zhizhen attended the forum to listen to the keynote lecture
The Cell Therapy International Summit Forum was successfully held, and experts and scholars at home and abroad gathered together to help the vigorous development of China's cell therapy industry.
Also participating in the event: Xu Haixiong, President of Shantou Academy of Medical Sciences; Jiang Jianli, Deputy Director of the National Center for Molecular Medicine Transformation, Air Force Military Medical University; Tan Xiaohua, Director of the Department of Medical Oncology, Shenzhen Third People's Hospital; Li Furong, Director of Collaborative Innovation Center for Translational Medicine, Shenzhen People's Hospital; Huang Xi, Academic director of the Fifth Affiliated Hospital of Sun Yat-sen University; Xing Fei, Director of the Second Department of Surgical Oncology, Shengjing Hospital of China Medical University , Tsinghua University School of Medicine Harihar Professor Basnet, Director Wu Zhihong of the Central Laboratory of Peking Union Hospital, Chinese Academy of Medical Sciences, Chairman Wang Jiannan of Shenzhen Faith Investment Management Co., LTD., Chairman CAI Fan of Shenzhen Shouzheng Innovative Traditional Chinese Medicine Development Foundation, President Zhang Congjie of Silver Star Group, Vice President Ye Xiulian of Silver Star Group, Chairman LAN LAN of Pingshan District Industrial Capital Investment Co., LTD., Guangming District, Shenzhen Zheng Xiaoli, vice president of New Materials Pilot Transformation Research Institute, Zhu Pengfei, Vice president of Shenzhen Guangming District New Materials Pilot Transformation Research Institute, Yang Shiying, General manager of Shantou Haiyi Investment (Group) Co., LTD., Liang Xiao, vice general manager of Beijing Xingdetong Pharmaceutical Technology Co., LTD., Chairman of Saiqiao Biocommercial Institute Fang, Chairman of Shenzhen Huahan Gene Life Technology Co., LTD., and Shenzhen Yawei Lv Jianxin, general manager of Investment Management Co., LTD., Zhang Lei, general manager of Beijing Huaxin Tianyuan Capital Management Co., LTD., and Yu Yuanzhi, secretary-general of Shenzhen Youth Science and Technology Talent Association, are leaders, industry leading experts and entrepreneurs.
The event was sponsored by Cell Medicine Branch of China Food and Drug Enterprise Quality and Safety Promotion Association, guided by Pingshan District Science and Technology Innovation Bureau, organized by Peking University Shenzhen Hospital, Shenzhen Cell Valley Biological Medicine Co., LTD., Shenzhen Pingshan District Industrial Capital Investment Co., LTD., Pingshan District Silver Star Life and Health Science Park, Cell Technology Network.
